Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H ( (HK:2185) ) has shared an update.
Shanghai Bio-heart Biological Technology Co., Ltd. has announced its 2024 Annual General Meeting (AGM) to be held on June 19, 2025, in Shanghai. The AGM will address several resolutions, including approval of the 2024 work reports, profit distribution plan, audited financial statements, and the re-appointment of auditors. A special resolution will consider the repurchase and cancellation of H Shares related to the 2022 H Share Incentive Scheme, which involves reducing the registered share capital and authorizing the management committee to handle related matters. This announcement reflects the company’s ongoing efforts to manage its financial and operational strategies effectively, potentially impacting its market positioning and shareholder value.
More about Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
Shanghai Bio-heart Biological Technology Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the biotechnology industry. The company focuses on developing biological technologies and solutions, with its market focus primarily in China.
Average Trading Volume: 302,357
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.08B
For a thorough assessment of 2185 stock, go to TipRanks’ Stock Analysis page.